Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

Documenti analoghi

• Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects
  di: Malhotra, Bimal, et al.
  Pubblicazione: (2011)
• The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers
  di: Walker, Gennyne, et al.
  Pubblicazione: (2009)
• Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers
  di: Malhotra, Bimal, et al.
  Pubblicazione: (2011)
• Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
  di: Li, Junfeng, et al.
  Pubblicazione: (2015)
• Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
  di: Liu, Yani, et al.
  Pubblicazione: (2019)